These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8956719)

  • 1. Intravenous immunoglobulin in the Guillain-Barré syndrome. May cause severe adverse skin reactions.
    Hamdalla HH; Hawkes CH; Spokes EG; Bamford JM; Goulding PJ
    BMJ; 1996 Nov; 313(7069):1399-400. PubMed ID: 8956719
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
    Gürses N; Uysal S; Cetinkaya F; Işlek I; Kalayci AG
    Scand J Infect Dis; 1995; 27(3):241-3. PubMed ID: 8539548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin in two children with Guillain-Barré syndrome.
    Notarangelo LD; Duse M; Tiberti S; Guarneri B; Brunori A; Negrini A; Ugazio AG
    Eur J Pediatr; 1993 Apr; 152(4):372-4. PubMed ID: 8482293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré syndrome in a 93-year-old woman: rapid improvement of neurologic function following intravenous immunoglobulin.
    Uldry PA; Bogousslavsky J; Regli F
    Schweiz Arch Neurol Psychiatr (1985); 1991; 142(4):301-5. PubMed ID: 1719624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second response to immunoglobulin in recurrent Guillain-Barré syndrome.
    Nagappan R; Barker J
    N Z Med J; 1998 Nov; 111(1077):433-4. PubMed ID: 9861925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune globulin therapy in children with Guillain-Barré syndrome.
    Goodhew PM; Johnston HM
    Muscle Nerve; 1996 Nov; 19(11):1490-2. PubMed ID: 8874410
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of intravenous immunoglobulins in Guillain-Barré syndrome].
    Ceccarelli M; Assanta N; Chiaravalloti G; Rocopou C; Caiulo VA
    Minerva Pediatr; 1992 May; 44(5):237-40. PubMed ID: 1620076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group.
    Ann Neurol; 1994 Jun; 35(6):749-52. PubMed ID: 8210234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
    Visser LH; van der Meché FG; Meulstee J; van Doorn PA
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compatibility problems after intravenous immunoglobulin--a case report.
    Sulochana PV; Mathai J; Sathyabhama S; Augustine P
    Indian J Pathol Microbiol; 1998 Oct; 41(4):495-8. PubMed ID: 9866917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome.
    Harkness K; Howell SJ; Davies-Jones GA
    J Neurol Neurosurg Psychiatry; 1996 May; 60(5):586. PubMed ID: 8778270
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunoglobulins i.v.: a new approach to the treatment of Guillain-Barré syndrome.
    Fasanaro AM; Pizza V; Rossi V
    Minerva Med; 1996; 87(1-2):17-20. PubMed ID: 8610020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
    Kleyweg RP; van der Meché FG
    J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin in the Guillain-Barré syndrome. Products with low IgA content may be used in patients with total IgA deficiency.
    Misbah S
    BMJ; 1996 Nov; 313(7069):1400. PubMed ID: 8956720
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome.
    Ng KK; Howard RS; Hirsch NP; Miller DH
    Neurology; 1993 Dec; 43(12):2729; author reply 2730-1. PubMed ID: 8255495
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous IgG in Guillain-Barré syndrome.
    Hughes RA
    BMJ; 1996 Aug; 313(7054):376-7. PubMed ID: 8761208
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose intravenous immune globulin in the management of severe Guillain-Barre syndrome.
    Baskin E; Turkay S; Icagasioglu D; Tanzer F; Cevit O
    Turk J Pediatr; 1996; 38(1):119-23. PubMed ID: 8819632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous immunoglobulins in Guillain-Barré syndrome].
    Hidou M; Olivier J; Vivant JF
    Ann Fr Anesth Reanim; 1992; 11(1):115. PubMed ID: 1443803
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe Guillain-Barré syndrome during childhood responding to intravenous gammaglobulin.
    Heaton PA
    N Z Med J; 1992 Nov; 105(946):477-8. PubMed ID: 1436876
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.